Zobrazeno 1 - 10
of 80
pro vyhledávání: '"N. Ozan"'
Autor:
Ender COŞKUNPINAR, Sakin TEKİN, Şükrü PALANDUZ, Hakan AVCI, Kıvanç CEFLE, N. Ozan TİRYAKİOĞLU, Ayşe KUBAT ÜZÜM, Refik TANAKOL, İlhan SATMAN
Publikováno v:
Bezmiâlem Science, Vol 6, Iss 2, Pp 126-129 (2018)
Objective:A 35-year-old Turkish male patient was referred to us with a year-long history of joint paint and congenital hearing loss. Family history revealed more family members with hearing loss without paraneoplastic syndrome. These findings led us
Externí odkaz:
https://doaj.org/article/7b1b6d715a4c4044bf609ae4faaa41ef
Autor:
TANRIKULU, Ebru1 tanrkuluebru@harran.edu.tr, BAKIR, N. Ozan2 obakir@marmara.edu.tr
Publikováno v:
Journal of Marmara University Social Sciences Institute / Öneri. Jul2021, Vol. 16 Issue 56, p634-667. 34p.
Autor:
AGHARZAYEV, Emil1 a.emil94@gmail.com, BAKIR, N. Ozan2 obakir@marmara.edu.tr
Publikováno v:
Journal of Administrative Sciences / Yonetim Bilimleri Dergisi. 2021, Vol. 19 Issue 39, p115-149. 35p.
Autor:
Pauline Lamoureux, Denis Moro-Sibilot, Thomas Egenod, P. Bombaron, Melinda Daumont, Audrey Rabeau, Adrien Dixmier, Christophe Raspaud, Nicolas Benoit, Didier Debieuvre, N. Ozan, Juliette Dumanoir, Bernard Asselain, Virginie Westeel, C. Calvet, Clarisse Audigier-Valette, Dorothee Reynaud, Victoria Allan, Fabrice Barlesi, François-Emery Cotté, Maurice Pérol, Jean-Bernard Auliac, Jérôme Fayette, Jean-Luc Labourey, Myriam Locatelli Sanchez
Publikováno v:
Oncoimmunology
article-version (VoR) Version of Record
OncoImmunology, Vol 9, Iss 1 (2020)
article-version (VoR) Version of Record
OncoImmunology, Vol 9, Iss 1 (2020)
EVIDENS is an ongoing, prospective, non-interventional study evaluating the effectiveness and safety of nivolumab in lung cancer patients in France (ClinicalTrials.gov NCT03382496). Adults with a pathologically confirmed diagnosis of lung cancer and
Autor:
Bakır, N. Ozan, Safarzade, Günay
Günümüzde tüketiciler sadece ihtiyaçlarını karşılayan ve onları memnun eden ürünlerden ziyade somut özellikler sunan, onlara farklı deneyimler sunan markaları tercih etmektedirler. Tüketici-marka ilişkisini iyi yöneten markalar, yo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_____10176::a2123e2fcb2b2ecb3a873dedd22c90a3
https://hdl.handle.net/20.500.12939/2014
https://hdl.handle.net/20.500.12939/2014
Autor:
Sibel Aydoğan, N. Ozan Bakir
Publikováno v:
Beykoz Akademi Dergisi. 6:90-110
Gunumuzde teknolojinin ilerlemesi, geleneksel medyadan yeni medyaya gecis surecinde onemli rol oynamistir. Ozellikle akilli telefonlarin fazlaligi, her sektorden cesitli firmalarin birbiriyle rekabet etmesinde akilli telefonlarda kullanilan uygulamal
Autor:
N. Ozan Tiryakioglu, Halime Hanım Pençe, H. Tunali, N. Ersoy Tunali, Sadrettin Pence, Emin Ozbek
Publikováno v:
Cellular and Molecular Biology. 63:46-52
To study the role of MMP9 and TIMP2 genotypes and expression in predisposition to bladder cancer and relation with metastasis. 100 urinary bladder cancer patients and 100 healthy controls were included in the study. rs3918242 and rs8179090 genotypes
The aim of this study is to investigate the effects of market orientation and brand orientation on firm performance. An integrative approach is used in designing the research model. Market orientation and brand orientation taken as antecedents of fir
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::21345c36bf3878e9ed260524383994ff
https://hdl.handle.net/11424/223754
https://hdl.handle.net/11424/223754
Autor:
Victoria Allan, F-E. Cotte, Adrien Dixmier, P. Bombaron, Bernard Asselain, Didier Debieuvre, D. Moro-Sibilot, N. Benoit, Clarisse Audigier-Valette, C. Raspaud, J. Dumanoir, Jean-Bernard Auliac, C. Calvet, N. Ozan, Fabrice Barlesi, Maurice Pérol, Dorothee Reynaud
Publikováno v:
Annals of Oncology. 31:S854-S855
Autor:
A. Dixmier, N. Ozan, N. Benoit, P. Bombaron, François-Emery Cotté, P. Lamoureux, C. Calvet, D. Debieuvre, C. Audigier-Valette, Jean-Bernard Auliac, Fabrice Barlesi, M. Daumont, C. Raspaud, M. Pérol, Denis Moro-Sibilot, Victoria Allan, Bernard Asselain
Publikováno v:
Revue des Maladies Respiratoires Actualités. 12:200-201
Introduction L’etude EVIDENS vise a evaluer l’efficacite et la tolerance du nivolumab utilise en conditions de vie reelle en France chez des pts atteints de cancer du poumon et a decrire leurs caracteristiques cliniques et leur qualite de vie. Me